Last updated on June 2019

Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)


Brief description of study

The purpose of this study is to evaluate vedolizumab pharmacokinetics (PK), safety and tolerability in pediatric participants with moderately to severely active UC or CD.

Detailed Study Description

The drug being tested in this study is called vedolizumab. Vedolizumab is being tested to treat pediatric participants who have moderately to severely active UC or CD. This study will look at the PK, efficacy, immunogenicity, safety, and tolerability in participants who take vedolizumab.

The study will enroll approximately 80 participants. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two dose regimens (high or low) per weight group >=30 kg and 10 kg to <30 kg in ratio 1:1which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):

  • Vedolizumab high dose group - Vedolizumab 300 mg or 200 mg
  • Vedolizumab low dose group - Vedolizumab 150 mg or 100 mg

All participants will be administered vedolizumab via IV infusion. Participants assigned to the low dose group who do not achieve clinical response (based on pediatric UC/CDAI) at Week 14 will receive the high dose (that is, 300 mg for participants >=30 kg baseline weight and 200 mg for participants 10 kg to <30 kg baseline weight) of vedolizumab IV at Week 14.

This multi-center trial will be conducted worldwide. The overall time to participate in this study is up to 36 weeks. After completing the Week 22 Visit procedures, eligible participants may enter an extension study. Participants will make multiple visits to the clinic, and those who do not enter extension study will have a final visit 18 weeks after last dose of study drug for a follow-up assessment. Participants who do not enter the extension study will also participate in a long-term safety follow-up, by telephone, 6 months after the last dose of study drug.

Clinical Study Identifier: NCT03138655

Find a site near you

Start Over

Cedars-Sinai Medical Center

Los Angeles, CA United States
  Connect »

Nemours Children's Clinic

Wilmington, DE United States
  Connect »

Mayo Clinic - Rochester

Rochester, MN United States
  Connect »

Northwell Health

Lake Success, NY United States
  Connect »

Mount Sinai Medical Center

New York, NY United States
  Connect »

Texas Children's Hospital

Houston, TX United States
  Connect »

University of Utah

Salt Lake City, UT United States
  Connect »

Seattle Children's Hospital

Seattle, WA United States
  Connect »

Hopital Robert Debre

Paris Cedex 19, France
  Connect »

Hopital de la Timone

Marseille Cedex 5, France
  Connect »

Isala Klinieken

Zwolle, Netherlands
  Connect »